Synchron Appoints Riki Banerjee as Chief Technology Officer

Riki Banerjee, Ph.D., Chief Technology Officer, Synchron (Photo: Business Wire)

NEW YORK–(BUSINESS WIRE)–Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO). Banerjee will be responsible for leading all research and development (R&D) activities, including advancing Synchron’s neuroprosthesis device for patients with severe paralysis. Banerjee will succeed Nick Opie, Ph.D., the founding CTO and co-founder of Synchron who remains on the Board of Directors.

“Riki has been an instrumental part of Synchron’s growth and has also been the driving force behind our product design”Post this

“Riki has been an instrumental part of Synchron’s growth and has also been the driving force behind our product design,” said Tom Oxley, CEO & Founder, Synchron. “She is a senior leader at the intersection of neuromodulation innovation, engineering, implantable medical devices and commercialization. Her expertise and leadership will be transformative as we accelerate our Synchron BCI device towards the industry’s first pivotal study. I would also like to thank Nick Opie, our founding CTO and co-founder, who will continue to play an important role as an active member of the Board.”

Riki joined Synchron in September 2021 as Vice President of R&D. She is a passionate technical leader and brings 12 years of demonstrated experience from Medtronic Neuromodulation where she had contributions as an engineer and organizational leader commercializing products across many therapies including deep brain stimulation, sacral nerve modulation, and spinal cord stimulation. Riki has led teams across engineering and scientific disciplines to translate medical technology to commercialized product.

“Synchron has developed an elegant new way to deliver a neuroprosthesis device to the brain that avoids many of the barriers of more invasive BCI approaches. I’m excited to lead the R&D and product team at this pivotal time of growth to advance this innovative neurotechnology to patients,” said Banerjee. “Synchron’s technology has the potential to change the lives of millions of people worldwide with upper limb impairment by delivering a first-in-class commercial BCI.”

Riki received a Ph.D. and Masters of Electrical Engineering from the University of Minnesota – Twin Cities. She received a Bachelors of Electrical Engineering from University of Wisconsin – Madison.

About Synchron

Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and restore autonomy for individuals with motor impairment. It is headquartered in New York City. For more information, visit www.synchron.com. Follow us @synchroninc.